You are here: Industry Insights > TAVO

News List

OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO Combined with KEYTRUDA for Late-Stage Metastatic Melanoma firstwordpharma
July 07, 2021
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration and Supply Agreement with Merck to to evaluate the combination of OncoSec's DNA-plasmid interleukin-12
Sirtex Medical announces collaboration update with OncoSec Medical prnasia
January 20, 2021
Sirtex Medical US Holdings, Inc. announced an advancement in its strategic collaboration with OncoSec Medical, Inc. relating to OncoSec's lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.
OncoSec Announces Initiation of aStudy to Evaluate Melanoma Treatment americanpharmaceuticalreview
August 31, 2020
OncoSec Medical Incorporated announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D. of the H. Lee Moffitt Cancer Center and Research Institute and ...
OncoSec Releases Interim Data from Ongoing Study of TAVO, KEYTRUDA® Combo americanpharmaceuticalreview
May 23, 2019
OncoSec Medical has announced interim data from KEYNOTE-890, an ongoing Phase 2 study of TAVO™ (intratumoral IL-12) in combination with KEYTRUDA® in patients with heavily pretreated ...
OncoSec, Gynecologic Oncology Group to Conduct Study of TAVO with KEYTRUDA americanpharmaceuticalreview
January 09, 2019
OncoSec has established a collaboration with the GOG Foundation to conduct a registration-enabled study of TAVO (tavokinogene telseplasmid) in women with recurrent/persistent cervical cancer (OMS-150)......